Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, was initiated in the outpatient setting, and it is the standard of care for stabilizing lung function and reducing disease progression in patients afflicted by LAM. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.